Net loss (USD, thousands)

Depreciation expense (USD, thousands)

Stock-based compensation expense (USD, thousands)

Non-cash lease expense (USD, thousands)

Changes in operating assets and liabilities: Accounts receivable (USD, thousands)

Changes in operating assets and liabilities: Prepaid expenses and other current assets (USD, thousands)

Changes in operating assets and liabilities: Other assets (USD, thousands)

Changes in operating assets and liabilities: Accounts payable (USD, thousands)

Changes in operating assets and liabilities: Right-of-use assets and operating lease liabilities (USD, thousands)

Changes in operating assets and liabilities: Accrued expenses and other current liabilities (USD, thousands)

Net cash used in operating activities (USD, thousands)

CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment (USD, thousands)

Net cash used in investing activities (USD, thousands)

CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock, net of underwriting discounts (USD, thousands)

CASH FLOWS FROM FINANCING ACTIVITIES: Payment of issuance costs (USD, thousands)

CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from exercise of stock options (USD, thousands)

Net cash provided by financing activities (USD, thousands)

NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH (USD, thousands)

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Property and equipment purchases in accounts payable and accrued expenses (USD, thousands)

Cash, cash equivalents and restricted cash at beginning of period (USD, thousands)

Cash, cash equivalents and restricted cash at end of period (USD, thousands)

bf0b399781e7bfc754c33844d86626895c701ec7e2e7aaf577c98ecb0b04b847

Service and other revenue (USD, thousands)

License revenue (USD, thousands)

Total revenue (USD, thousands)

Research and development expenses (USD, thousands)

General and administrative expenses (USD, thousands)

Total operating expenses (USD, thousands)

LOSS FROM OPERATIONS (USD, thousands)

Dividend income (USD, thousands)

Other expense, net (USD, thousands)

Total other income (expense), net (USD, thousands)

Loss before income taxes (USD, thousands)

Income tax provision (USD, thousands)

Net loss attributable to common stockholders—basic and diluted (USD, thousands)

Net loss per share attributable to common stockholders—basic and diluted (USD)

Weighted-average common stock outstanding—basic and diluted (Shares)

5344e8ab0cc4e1800e592b2838a39129c6d30beb238f52aeac70a610094c9446

Cash and cash equivalents (USD, thousands)

Accounts receivable (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Operating lease right-of-use assets (USD, thousands)

Property and equipment, net (USD, thousands)

Restricted cash (USD, thousands)

Other long term assets (USD, thousands)

TOTAL ASSETS (USD, thousands)

Accounts payable (USD, thousands)

Current portion of operating lease liabilities (USD, thousands)

Accrued expenses and other current liabilities (USD, thousands)

Total current liabilities (USD, thousands)

Operating lease liabilities, net of current portion (USD, thousands)

Total liabilities (USD, thousands)

Common stock (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated deficit (USD, thousands)

Total stockholders’ equity (USD, thousands)

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (USD, thousands)

cdaec86fa11a38ef976be5b8b2fc2455f7e336cfe1955587ee28d6eb464fb2f1

Service Revenue

- Tech Transfer Agreement

Other Revenue

- Supply Agreement

License Revenue

Total Revenue

d7192736a3a954f5b47751c921a7b7590131cd28b78ba4c0c5424cbbbf2128ce

Keros Therapeutics Inc (KROS)

Financials